SCHEMBL22897201

SCHEMBL22897201

NC(=O)C(=O)C(Cc1csc2ccccc12)NC(=O)c1nsnc1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 2/20 0.45
▸ CAPN1 P07384 9/20 0.41
▸ CTSL P07711 1/20 0.40
▸ CTSS P25774 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ TACR1 P25103 1/20 0.39
▸ MMP2 P08253 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP8 P22894 1/20 0.38
▸ CALCRL Q16602 1/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.36
▸ JUN P05412 1/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ MAPK9 P45984 1/20 0.36
▸ CASP1 P29466 1/20 0.35
▸ KLKB1 P03952 1/20 0.35
▸ KLK1 P06870 1/20 0.35
▸ CYP2A6 P11509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22896930 0.95 F10 (0.43) F10CAPN1CTSLCTSSCTSK
SCHEMBL22896286 0.91 F10 (0.42) F10CAPN1CTSLCTSSCTSK
SCHEMBL22896818 0.90 F10 (0.45) F10CAPN1CTSLCTSSCTSK
SCHEMBL22896715 0.88 CAPN1 (0.42) F10CAPN1CTSLCTSSCTSK
SCHEMBL22896917 0.83 CAPN1 (0.49) CAPN1CTSS
SCHEMBL20028431 0.82 CAPN1 (0.53) CAPN1CTSLCTSS
SCHEMBL21854063 0.82 CAPN1 (0.53) CAPN1CTSLCTSS
SCHEMBL22897103 0.82 CAPN1 (0.44) CAPN1
SCHEMBL21854296 0.82 BBOX1 (0.51) CTSLTACR1
SCHEMBL21854216 0.80 CAPN1 (0.52) CAPN1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 F10 4552/4885CAPN1 3/4885CTSL 234/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 F10 4424/4885CAPN1 4/4885CTSL 242/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 F10 4552/4885CAPN1 3/4885CTSL 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback